Tennr
Tennr develops a healthcare workflow automation platform using its AI model, RaeLM™, to interpret medical records and manage referrals.
Secondary Market Price
Secondary Market Price
How Tennr Measures Up
To help you manage your Tennr equity, Prospect has run the company through our machine learning model.
Prospect Rating
5X
Based on our analysis, we rate Tennr with a potential 5X increase in value over the next four years. For an employee with equity, this suggests a significant potential for their stock options to grow in value.
Exit Risk
High Risk
Our 'High Risk' rating reflects that while Tennr is scaling quickly and is backed by top investors, the path to a liquidity event for an early-stage company is inherently uncertain.
Funding Stage
Series C
A Series C funding round suggests Tennr is a more established company with a proven track record. For a potential employee, this often means a balance of stability found in larger companies with the impactful growth opportunities of a startup.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Tennr's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Tennr Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Tennr's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Tennr is a software development company that provides a workflow automation platform for healthcare operations. The platform is designed to track patient referrals, verify information, and automate manual back-office tasks. It utilizes a vision-language model, RaeLM™, to interpret unstructured medical documents against payor criteria, with the goal of reducing claim denials and improving documentation accuracy for healthcare providers like specialty pharmacies and home infusion care companies. Founded in 2021 by Trey Holterman, Tyler Johnson, and Diego Baugh, the New York-based company has since grown to employ between 201 and 500 people.
The company's recent activities indicate a focus on expansion. In mid-2025, Tennr raised $101 million in a Series C funding round, bringing its total funding to approximately $159 million with backing from investors including IVP, GV, and Andreessen Horowitz. The company also recently announced a strategic partnership with KabaFusion, a home infusion care provider, to apply its AI technology to reduce administrative tasks. In addition, Tennr launched a free diagnostic tool designed to help providers group claim denials by their root cause and is actively involved in industry discussions regarding upcoming regulatory changes, such as the CMS 2025 Proposed Rule.
- Andreessen Horowitz
- Y Combinator
- GV
- IVP
- ICONIQ
- Foundation Capital
- Co-Founder, CEO Trey Holterman
- Co-Founder, CPO Diego Baugh
- Co-Founder, CTO Tyler Johnson
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Tennr worth joining?
Tennr is an early-stage, high-risk company that is scaling quickly and backed by top investors like Andreessen Horowitz and Y Combinator. To determine if it's the right fit for your career goals, you can use a platform like Prospect to evaluate the potential value of its equity and compare it to other startups.
What should I do with my Tennr stock?
Managing private company stock like Tennr's involves complex decisions about when to exercise options and how to minimize taxes. Platforms like Prospect provide tools and personalized strategies to help you maximize the value of your equity compensation.
Can you sell Tennr stock?
As a private company, Tennr stock is not publicly traded, but employees may be able to sell shares through secondary markets or tender offers. Tools from platforms like Prospect can help you navigate these private sales and identify tax-optimal times to sell.
How can I find the value of my Tennr stock?
While Tennr's latest valuation is estimated between $100M and $250M, determining the specific value of your shares requires more detailed analysis. You can use platforms like Prospect, which offer predictive models and equity calculators to get a personalized projection of your stock's worth.
What is Tennr's equity worth?
Tennr's latest valuation is estimated to be between $100 million and $250 million. The actual value of your personal equity stake depends on factors like the total number of shares and the specific terms of your grant.
What is Tennr's stock ticker symbol?
Tennr is a private company, so it is not traded on a public stock exchange and does not have a stock ticker symbol. Only public companies that are listed on exchanges like the NYSE or NASDAQ have ticker symbols.
Can I buy or sell Tennr stock?
Buying shares in Tennr is likely restricted to accredited investors and venture capital firms, as it is a private, venture-backed company. Selling shares is also restricted and typically only possible through company-approved secondary sales or tender offers.
What is the criteria to buy or invest in Tennr stock?
As a Series B startup, investment in Tennr is generally limited to accredited investors and institutional venture capital firms that participate in private funding rounds. The company does not offer shares for purchase to the general public.
